insights_auto
Why is GRAL down 3.19%?
Dive Deeperchevron_right
GRAL:NASDAQ
Grail Inc
$132.90
arrow_downward
-3.19%(-4.38) 1D
$130.56
arrow_downward
-1.76% (-2.34)todayPre-market
Closed: Oct 7, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$134.00
High
$139.00
Low
$130.56
Mkt. cap
5.94B
Avg. vol.
1.23M
Volume
1.71K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
Open
$134.00
High
$139.00
Low
$130.56
Mkt. cap
5.94B
Avg. vol.
1.23M
Volume
1.71K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
News stories
From web sources and news partners
Kalkine Media
·
10 hours ago
GRAIL's Chief Growth Officer Andrew Partridge Sells 7,873 Shares to Cover Tax Withholding
Investing.com
·
11 hours ago
Grail CFO Aaron Freidin sells $3.46m in company stock
Investing.com
·
11 hours ago
Grail chief growth officer Andrew Partridge sells $1.15m in stock
Investing.com Canada
·
11 hours ago
Form 4 Grail Inc For: 7 October By Investing.com
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegrail.com